Key facts
- Notable investors include Enterprise Ireland, Cepheid, MedTech Syndicates.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for OncoAssure
- ·The full record, as it builds
Funding rounds
No funding rounds for OncoAssure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OncoAssure
Developer of oncology diagnostic biomarkers designed to improve cancer management and treatment. The company offers molecular assays that deliver prognostic information for early-stage cancers, such as prostate cancer, enabling healthcare providers to make informed treatment decisions and improve patient outcomes.
- Sector
- Healthcare
- HQ
- Dublin, Ireland
- Founded
- 2021
- Employees
- 10
- Website
- oncoassure.com/
- Ownership
- Privately Held (backing)
OncoAssure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OncoAssure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OncoAssure in its N-PORT filings yet. We sweep new filings monthly.